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The B7 adhesion molecule, a member of the immunoglobu-
lin superfamily, has previously been identified primarily on 
cells of hematopoietic origin. Because B7 has been shown to 
facilitate interactions with T cells and because cells of the 
epidennis are proficient at binding and activating T lympho-
cytes, studies were performed to determine whether B7 was 
expressed in human epidermis . A subpopulation of brightly 
staining B7-positive cells was observed in situ in normal 
human epidermis. Flow-cytometric examination of epider-
mal cell suspensions that had been cultured for 24 h or longer 
I nflammatory and immunologic reactions within the skin are highly regulated processes that are mediated to a large extent by chemotactic factors, cytokines, and cytokine receptors. Receptor-ligand interactions between adhesion molecules present 011 the surface of different cell types are also impor-
tant for the development, progression, and resolution of these reac-
tions. Adhesion molecules mediate their effects by regulating cellu-
lar migration patterns, promoting homotypic and heterotypic cell 
binding, and facilitating cellular communication among different 
cell types [1]. Keratinocytes have been observed to express at least 
two adhesion molecules that support T-cell interactions with the 
epidermis. These are intercellular adhesion molecule-1 (ICAM-1) 
. and lymphocyte function-associated antigen-3 (LFA-3), which 
bind to LFA-1 and C02, respectively, on the surface ofT cells [2]. 
ICAM-1 is not expressed on normal keratinocytes, but can be ex-
pressed in situ during inflammatory conditions and on cultured ker-
atinocytes following treatment with tumor necrosis factor-alpha 
(TNF-a) and interferon-gamma (IFN-y) [3- 5]. Expression of this 
molecule has been shown to facilitate binding and signal transduc-
tion between LFA-1-positive T cells and keratinocytes [5] . Cell-
surface expression ofLFA-3 has also been detected on keratinocytes. 
Its role in cutaneous T-cell inflammatory processes is less well un-
derstood. However, it does serve as an adhesion molecule to which 
C02-positive T lymphocytes can attach. 
B7, a 44/54-kOa member of the immunoglobulin supergene 
family, has been recognized to be an adhesion molecule on B lym-
phocytes [6,7] . It has also been referred to in the literature as BB-1 
and B7/BB-1. Its natural ligands are C028 and CTLA-4 on T cells 
[8-10] . B7/BB-1 has been shown to stimulate Tcells by binding to 
the C028 molecule [11], and this interaction leads to increased 
T-cell proliferation and cytokine production [12,13] . Besides these 
quantitative effects, signal transduction through C028 stimulates T 
cells in a qualitatively unique way in that interleukin-2 secretion 
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demonstrated that between 10 and 40% of cells expressed B 7 
or a closely.related antigen. Il11muno:lec~ron microscopy , 
double-stall1ll1g procedures, and eXamll1atlOn of epidermal 
suspensions depleted of Langerhans cells all confirmed that 
the B7-positive cells were keratinocytes. These studies iden-
tify human epidermal keratinocytes, a non-hematopoietic 
cell population, as a cell type capable of expressing a B7 -like 
adhesion molecule. Key words: CD28/Langerhans cells/ 
keratinocyte. ] Illvest Dennatol1 01:754 - 758, 1993 
initiated via the C028-B7 interaction is not inhibited by cyclo_ 
sporin A [14]. There is evidence that the receptor-ligand interaction 
with B7 promotes B-cell differentiation as well [13]. B7 has also 
been detected on activated monocytes [8], on dendritic cells [15,16]. 
and on munne pentoneal exudate cells [17] . Recently. expression of 
a B7-like molecule has been demonstrated in lIitro on activated 
cultured keratinocytes [18,19] and on human Langerhans cells ~ 
epidermal cell cultures [20]. 
The focus of our experiments was to determine whether B7 wa 
present in situ in the epidermis and, if so, to determine the cell type 
expressing the B7 molecule. Because other investigators have found 
that B7 is involved in the T-cell activation process, and, within the 
epidermis, antigen presentation is largely attributed to Langerhans 
cells, it seemed likely that this cell type might express B7. We were 
surprised to find that B7 was present on epidermal keratinocytes and 
was not expressed by freshly prepared human Langerhans cells. 
MATERIALS AND METHODS 
Antibodies Purified BB-l, a murine monoclonal antibody of the IgM 
class specific for the B7 antigen, was the generous gift of Dr. Edward A. 
Clark, University of Washington, Seattle, W A [6]. The antibody was puri. 
fied from ascitic fluid by ammonium sulfate precipitation. In some experi_ 
ments, BB-l was conjugated with fluorescein isothiocyanate (F1TC) and 
then used for staining purposes. Other primary monoclonal antibodies used 
were anti-HLA-DR (Becton Dickinson Co., Mountain View, CAl. anti. 
COla (OKT6, Ortho Immune Diagnostic, Raritan. NJ), anti-desmogl~ 
(Boehringer-Mannheim, Indianapolis,IN),lgM (Calbiochem Corporation 
La Jolla, CAl, colloidal gold- and F1TC-col~ugated anti-mouse IgM (Ch'; 
micon, Inc., Temecula, CAl, and anti-mouse IgG-FITC (Chem.icon. Inc. 
Temecula, CAl. 
E" face Staining of Epidermis Sheets .of epidermis were obtained by 
removlDg the roofs of vacuum-lIlduced suctIOn blIsters from the forearms of 
human volunteers as previously described [21]. The sheets were fixed in cold 
acetone, washed in phosphate-bnffere.d sa line (PBS), and then incubated 
with the appropriated primary monoclonal antibody (MoAb) for 18 h at 
4°C. Primary antibodies used were BB-l (7.4 J.lg/ml), non-cross-reacti\'~ 
IgM (7.4 /lg/ml), anti-CDla (5 /lg/ml), and anti-HLA-DR (10 J.lg/rnI). 
The sheets were again washed in PBS to remove unbound antibody and wm-
then treated with either FITC-conjugated anti-mouse IgM (100 J.lg/m1) at 
IgG (100 /lg/ml) , depending on the immunoglobulin class of the prima!}' 
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Figure 1. Staining of epidermal sheets. Horizontal sections of normal 
human epidermis were incubated with (a) BB-l, 7.4 Jig/ml, (b) anti-COla 
(OKT6).? ,ug/ml, or (c) non-cross-reactive IgM, 7.4Jig/ml. The secondary 
anribody In a ll three tissue preparations was FITC-conJugated antl-mouse 
IgM. Bar, 25 Jim. 
anribody. The sheets were again washed, mounted on sl ides with glycerine 
and examined with a Nikon immunofluorescence microscope. 
Preparation of Epidermal Cell Suspensions Fresh human cadaver 
skin was obtained within 24 h of death and was taken only from individuals 
with no known infectious disease who were under 40 years of age. Subcuta-
neous fat was removed from the skin specimens, which were then cut into 
2 X 10 mm strips. The strips were then placed dermal side down in 0.5% 
dispase (Boehringer-Mannheim, Indianapolis, IN) and incubated for 24 h at 
4' C. At the end of the incubation period, epidermis was separated from 
dennis and was placed in 0.15% trypsin (ICN Biochemicals, Inc., Cleveland, 
DH) for 60 min at 37'C. At the end of the trypsinization period, the 
disaggregation process was completed by vigorously pipetting the specimen 
for several minutes. 0.25% DNAse (Sigma Chemical Co., St. Louis, MO) 
was then added for 5 min, after which the cells were washed in culture 
medium. Cell viabi lity, as determined by trypan blue exclusion, was rypi-
cally greater than 90%. 
Staining ot Epidermal Cell Suspensions for Flow Cytometry 
Freshly prepared epidermal cel ls or cells that were incubated for various 
periods of time (as indicated in the Results) were stained with FITC-labcled 
8B-l or non - cross-reactive FITC-Iabeled IgM. As a positive contro!' Ep-
stein-Barr virus (EBV)-transformed B cel ls were stained with the same 
antibodies, Incubation was for 30 min at 4 'C using an antibody concentra-
tion of 7.4 ,ug/m!' Fluorescence measurements were made on a flow cyto-
meter (Cytofluorograph lIs, Ortho Instruments, Westwood, MA) using the 
488-nm line of an argon laser operating at 200 to 300 mW. Propidium 
iod ide (1 J.lg/ml) was added to each sample 5 min prior to fluorescence-
2Ctivated cell sorter to exclude dead cells. 
Two-Color Analysis of Epidermal Cell Suspensions for Immunoflu-
orescence Microscopy Epidermal cells were incubated with the antibody 
combinations 13B-l/anti - HLA-OR, BB- l/anti-COla, and BB-l/anti-des-
moglein each for 30 min and 4 'c. Antibody concentrations used were BB-l, 
7.4 J.Lgjml; anti-HLA-DR. 10 Jig/ml; anti-COla, .5 Jig/m.i; and anti-?es-
rnoglcin, 10 ,ug/m!' The cells were washed twice 111 10% culture medIUm 
and incubated with a secondary anti-mouse IgG (100 Jig/ml) or IgM (100 
Jig/m!) conjugated to either FITC or phycoerythrin (PE) for 30 min at 4 ' c. 
Cells were "Washed twice in 10% culture medium and examined on an 
immunofl uorescence microscope using the appropriate filters for FlTC 
and PE. 
Depletion ot Langerhans Cells from Epidermal Cell Suspensions 
Freshly prepared epidermal cell suspensions (t07/ml) were incubated for 30 
min with anti-COla monoclonal antibodies at 4 ' C. The cel l suspensions 
were washed and then incubated on a rocker panel with goat anti-mouse 
IgG-coated Dynabeads (Oynal, Inc., Great Neck, NY). The bead to target 
,dl rario was 10 : 1. Following incubation at 4 'C, beads and bead-coated 
Langerhans cells were removed from the cell suspension using a Magnetic 
Particle Concentrator (Oynal, Inc., Great Neck, NY). 
Immunoelect:ron Microscopy Epidermal cell suspensions that had been 
incubated for 24 h were incubated with BB-l or nOll- cross-reacting IgM at 
KF.RATINOCYTE EXPRESSION OF A B7-LIKF. ADHESION MOLECULE 755 
No Incubation 
100 
EC .. 19M EC + BB-l/B7 
100 
a b 
Qi 
.Q 
E 
::l 10 Z 10 
a; 
() 
0 O+--r~~.-~--~ 
100 200400 600 8001000 100 200 400 600 8001000 
Immunofluorescence 
48 Hour Incubation 
EC .. 19M EC + BB-l/B7 
100 100 
C d 
Qi 
.c 
E 
::l 10 10 Z 
a; 
() 
0 0 
100 200400 600 8001000 100 200400 600 8001000 
Immunofluorescence 
100 
Depleted EC .. 19M Depleted EC + BB-l/B7 
100 
Qi e 
.c 
E 
::I 10 10 Z 
a; 
() 
0 0 
100 200400 600 8001000 100 200400 600 8001000 
Immunofluorescence 
Figure 2,. Flo,,:, cytometry. Cell suspensions were prepared from normal 
human epidermiS and stamed for flow cytometric analysis using either non-
cross-reactive IgM (a , c, and e) or BB-l (b, d, andf) as the primary anribody. 
a,b) Cell suspenslOlIs stained immediately fo llowing disaggregation. c,d ) 
Cell suspensIOns mcubated for 48 It prior to staining. eJ) Cell suspensions 
depleted of Langerhans cells and incubated for 48 h prior to staining. 
7.4 Jig/ml for 30 min at 4 'c. After washing twice, the cells were incubated 
with gold-labeled anti-mouse IgM for 30 min at 4' C and were aga in 
washed. The cell pellet was fixed with 3% glutaraldehyde in 0.1 M caco-
dylate buffer. It was then embedded in a polymer resin, sectioned, and 
examllled on a Jeol 100CX transmission electron microscope. 
RESULTS 
I~ situ Ident!fication o~ B7-Positive Cells in en face Pre para-
bO.ns of E~)1dermal Tlssue Sheets of normal epidermis were 
staIned for lmmUllOfluorescence microscopy with BB-1 to deter-
mine whether this molecule was expressed ill situ. Substantial num-
bers of B7-positive cells were identified (Fig 1a). The positively 
stained ~ells w~re present in clusters and had a rounded morphol-
ogy. TIllS stallung 'pattefl~ contrasted with that seen when epider-
mal sheets were stamed With antl-CD1a MoAb to detect epidermal 
Langerhans cells (Fig 1b). With anti-CD 1 a, positively stained cells 
were diffusely distributed and exhibited a dendritic morphology 
charactenstlc of Langerhans cells. Because £B-1 is an IgM class 
antibody, control epiderma l sheets were stained using non-cross-
reacting IgM as the primary reagent. Only background staining was 
observed (Fig le). 
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Table I. Flow-Cytometric Analysis of Epidermal Cells 
Stained for B7' 
Cell Type 
Epidermal cells, 48-h incubation 
EBV-transformed B cells 
Mean Fluorescence Intensity 
Anti-137 (BB-l) 
49.6 
38 .9 
IgM Control 
3.1 
8.2 
• Cells were stained with either BB-! (7.4 /lg/ml) or murine non -cross-reactive IgM 
(7.4 /lg/ml) as the primary antibody. The secondary antibody in both cases was FITC-
conjugated anti-mouse IgM (100 pg/m l). Mean fluorescence intensiry is expressed in 
arbitrary units. 
Identification of B7-Positive Cells in Suspension of Epider-
mal Cells B7-positive cells could also be identified in epidermal 
cell suspensions following trypsin disaggregation. In most in-
stances, few, if any, B7-positive cells could be detected immediately 
after trypsinization (Fig 2a,b). Expression of the B7 antigen became 
apparent after 24 h and was upregulated when cells were cultured 
for longer periods of time. After 48 h in culture, a large proportion 
of the cells, ranging from 10 to 40%, was B7 positive (Fig 2c,d) . 
EBV -transformed B cells were used as a positive control (Table 1). 
The large percentage of epidermal cells staining positively for B7 
suggested that keratinocytes were the predominant cel! type to ex-
press this molecule. To examine this issue further, HLA-DR-
positive Langerhans cells were removed from cell suspensions prior 
to the staining procedure. Preliminary studies established that the 
depletion procedures rendered cell sllSpensions devoid of CDla-
and HLA-DR-positive cells (data not shown). No difference in 
fluorescence intensity among depleted and non-depleted epidermal 
cell popnlations was observed (Fig 2e,J). Similar results were ob-
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tained when anti-CDla MoAb was employed to remove Langer-
hans cells from the preparations (data not shown) . 
Immunoelectron Microscopy lml11unoelectron microscopy 
was performed to determine definitively the type of cell expressing 
the B7 adhesion molecule. Unfractionated e~iderl11a l cell suspen-
sions that had been cultured for 24 h were first Illcubated with BB-l 
and were tben treated with go ld-labeled anti-mouse IgM. Gold 
beads cou ld be easily identified on the surface of ce lls (Fig 3, inset) . 
All ceUs labeled with BB-l possessed abundant keratin filaments 
and desl11osomes (Fig 3). None of the cells examined had the ultra-
structural characteristics of Langer hans cells or melanocytes. More-
over, gold-labeled cells were not observed when a non- cross-
reacting IgM antibody was substituted as the primary reagent (data 
not shown). 
Double Staining of Epidermal Cell Suspensions Keratino_ 
cytes cultured for 48 h were stained with both BB-l and anti-des_ 
mog~ein, a ~esmo~omal protein. present only on keratinocytes 
wlthm the ep~dermls (~lg 4). Prelllmnary .tests established that IgG 
secondary antibodies did not cross react With IgM primary antibod_ 
ies and that IgM secondary antibodies did not cross react with IgG 
primary antibodies (data not shown). Approximately half of the 
desmoglein-positive cells were B7 positive, providing further evi_ 
dence that keratinocytes express B7. HLA-DR-positive and 
CD la-positive Langerhans cells did not stain positively for BB-! in 
double-staining studies (data not shown). 
DISCUSSION 
These studies demonstrate that a B7-like adhesion molecule can be 
found i,l situ 011 epidermal cells, specifically human keratinocytes, 
This was definitively demonstrated by two-color immunofluores_ 
Figure~. lmmunoelectron microscopy. Epidermal cell suspensions were incubated with BB-l followed by colloidal gold-conjugated anti-mouse IgM. A 
representative cell is shown here (magnification X 5000). Labeled antibody (",row) bound to the cell surface can be seen on the il/se! (il/se! enlarged 4X). Bar, _ 
j.Lm. 
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Figure 4_ Two-color immunofluorescence microscopy using BB-l and 
anti-desmogJein. Epidermal cell suspensions were stained for B7/ BB-l 
(FITe-conjugated secondary antibody) and antl-desmogletn (PE-conJu-
ated secondary antibody). a, b, and c are from the same field and tillS field IS 
~epresen.t:~t:ive of the cells exa~ined. a, B7/BB-l- positive cells. b; Desmog-
lein-posltlve cells. c, normal hght. Bar, 25 J.1.m . 
cence when B7-positive cells were observed to be desmoglein-~osi­
tive and by immunofluorescence microscopy when B7-posltlve 
cells were found to contain the ultrastructural components of kera-
tinocytes . More importantly, this B7-l ike adhesion molecule was 
expressed in situ in epidermal sheets , suggesting that the molecule 
may h ave an important ill llillO role in keratinocyte - T cell interac-
tions. 
T he function of this B7 -like mol ecule on keratinocytes is open to 
speculation. For B cells [12,13] and murine dendritic cells [15], B7 is 
an important costimulatory molecule for T-cell activation. B7 may 
play a similar function on keratinocytes. Although Langerhans 
cells, rather than keratinocytes, have traditionally been considered 
to be the major antigen-presenting cell of the epiderml.s, keratll1o-
cytes can, in certain circumstances, perform this funct10n as ,:,ell. 
For example, keratinocytes induced to express class II major hlst~­
compatibility complex molecules by IFN-y can stimulate allogeneic 
T cells to proliferate when interleukin-2 is added to the cultures 
[2223]. Phorbol myristate ace tate- treated keratinocytes have al~o 
bee~ shown to be effective antigen-presenting cells for allogeneic 
responses without the addition of exogeI~ous cytokmes [24]. Pre-
liminary studies from our laboratory II1dlcate that epidermal cell 
lines devoid of Langerhans cells provide all the necessary accessory 
signals for T-cell activation by the bacterial superantigen staphylo-
coccal enterotoxin B. The addition of anti-B7 antibodies substan-
tially inhibits T-cell proliferation in this system (T. E. Flemll1g and 
C. A. Elmets, manuscript in preparation). 
B7 may be important for other bio logic activities within the 
epidermis .as well. Specifically, B~ may serve as a homing receptor 
for migrating T lymphocytes and Its expressIOn may be enhanced 111 
cutaneous diseases associated with an inflammatory infiltrate. B7 
expression may be particularly relevant for recruitment of cytotoxic 
T cells to the epidermis because B7 has recently been found to be a 
ligand for CTLA-4, a molecule found on a subpopulation of cyto-
toxic T cells [9] . 
Our inability to identify B7 on epidermal Langerhans cells was 
based on our observations that no cells were both HLA-DR positive 
2nd B7 positive, that all B7-po~itive cells stained with ?esmoglein 
anribodies, and that all B7-posltlve cells contamed kcratm filaments 
and desmosomes by immunoelectron microscopy. This findin g was 
somewh at surprising because cultured murine Langerhans cells 
have been shown to express this molecule [15]. It is important to 
mess that our studies do not exclude the possibility that human 
Langerhans cells express the B7 molecule under special conditions. 
Langerhans cells have been show~ to ~lcrease th.ei~ .cell-surface 
expression of CD54 and class II major 111StoCOmpaubility complex 
determinants w hen placed in culture [25 ,26]. In murine systems 
such changes have been associated with an enhanced capacity to 
present antigen to T lymphocytes [27]. It is certainly possible th at 
cultured human Langerhans cells also begin to express B7 under 
these conditions. A second possibili ty is that the BB-l monoclonal 
antibody recognizes an epitope on a B7-like molecule expressed by 
keratinocytes and that this epitope does not exist on Langerhans 
cells expressing a different B7-like molecule. This second possibil-
ity is supported by two recent reports. In one study, activated, cu l-
tured keratinocytes stained positively for BB-l but not with other 
anti-B7 monoclonal antibodies [1 9]. In the second study, investiga-
tors using a CTLA-4-Ig fusion protein have detected B7 on cul-
tured Langerhans cells but not on cultured keratinocytes [20] . 
The role of th e B7 adhesion molecule in cutaneous immunobiol-
ogy and in the pathology of cutaneous inflammatory disease re-
n~ains t~ b.e determined. A number of skin diseases including aller-
gic and Irritant contact dermatitis, psoriasis, bullous drug eruptions, 
and graft-versus-host disease are associated with a lymphoid infil-
trate in the epidermis. Although other adhesion molecules have 
been shown to facilitate T -cell binding to the epidermis, the consti-
tutive expression of a B7-like molecule on keratinocytes suggests 
that it may play a ro le as well. 
In summary, keratinocytes express an adhesion molecule ill sitll 
that shares binding domains with B7 based on cross reactivity with 
the anti-B7 monoclonal antibody BB-l. This mol ecule is either B7 
itself or a closely related molecul e. B7 has been identified on various 
cell types, primarily of hematopoietic origin, and costimulates T 
cells via interaction with CD28 and CTLA-4. Its role in cutaneous 
immunobiology and in the pathology of cutaneous inflammatory 
and immunologic diseases remains to be determined. 
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